""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Back to alphabetical index

 

Dale Haines, PhD

dale Haines, PhD

 

Associate Professor, Biochemistry

Associate Professor, Fels Institute for Cancer Research and Molecular Biology

Telephone:  215-707-5765

Fax:  215-707-2805

Email: dhaines@temple.edu

 

Department of Biochemistry

Fels Institute for Cancer Research and Molecular Biology

 

Educational Background:

 

BA, Biology, University of Delaware, Newark, DE, 1988

PhD, Molecular Biology, Hahnemann University, Philadelphia, PA, 1992

Postdoctoral fellowship, Molecular Oncology, University of Pennsylvania School of Medicine (laboratory of Donna George), Philadelphia, PA, 1994

 

Visiting Scholar, Proteomics, California Institute of Technology, Pasadena, CA, Summers 2010-2012

 

Return to top

 

 

Research Interests:

 

ERGIC-53 is a ER-localized protein that functions in moving client proteins from the ER to a poorly understood sub-cellular structure called the ERGIC. The ERGIC is currently thought to be a sorting station that routes proteins for delivery to the Golgi and retrograde transport of ERGIC-53 back to the ER. In addition, it has been hypothesized to function in protein folding and quality control of secretory proteins that have departed the ER. The current focus of the Haines’ lab is to define using LC-MS/MS based approaches the content of ERGIC-53 containing vesicles and determine how newly identified ERGIC-53 interacting proteins comprised of p97-UBXD1 and Rab3GAP1/2 complexes control the trafficking and function of these vesicles in human cells. As some recently identify contents of ERGIC-53 vesicles have been shown to function in autophagy and tumor cell metastasis, there is a particular in defining the role of ERGIC-53 and interacting proteins in these processes.

 

Return to top

 

 

LABORATORY PERSONNEl:

 

Former Laboratory Members:

  • Yi Pan, PhD (Senior Biologist, Merck Pharmaceutical)
  • Natalia Shcherbik, PhD (Instructor, Rutgers University)
  • Chris Carbone, PhD (Research Associate, University of Pennsylvania)
  • Sabyasachi Bhattacharya, PhD (Postdoctoral Fellow, University of Pennsylvania)
  • Steve Beauparlant, PhD (Postdoctoral Fellow, Tufts University)
  • Dane Kyle, MS (Dental Student, Temple University)


Return to top

 

 

FUNDING HISTORY:

 

R01 GM070769, Haines (Principal Investigator), 2005-2010

Title-Ubiquitin Ligase Dependent Release of ER-bound Transcription Factors: The goal of this study is to elucidate the mechanism by which ubiquitination promotes the release of the ER localized transcription factors Mga2p and Spt23p.

 

P01CA095568, Reddy, Graña and Haines (Co-Investigators), 2003-2009

Title: G1 Cell Cycle Control and Tumorigenesis: My component of this project was to define cooperativity between the INK4 family of inhibitors and p21 in cellular transformation and define a role for MTBP in tumorigenesis.

 

R29CA070165, Haines (Principal Investigator), 1997-2003

Title: Functional Analysis of MDM2 overexpression: The goal of this project was to define p53 independent activities of the MDM2 onco-protein.


Return to top

 

 

PUBMED PUBLICATIONS :


Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

23775125. Kurimchak A, Haines DS, Garriga J, Wu S, De Luca F, Sweredoski MJ, Deshaies RJ, Hess S, Graña X, Activation of p107 by fibroblast growth factor, which is essential for chondrocyte cell cycle exit, is mediated by the protein phosphatase 2A/B55a holoenzyme. Mol Cell Biol 33:16(3330-42)2013 Aug

22337587. Haines DS, Lee JE, Beauparlant SL, Kyle DB, den Besten W, Sweredoski MJ, Graham RL, Hess S, Deshaies RJ, Protein interaction profiling of the p97 adaptor UBXD1 points to a role for the complex in modulating ERGIC-53 trafficking. Mol Cell Proteomics 11:6(M111.016444)2012 Jun

21103003. Haines DS, p97-containing complexes in proliferation control and cancer: emerging culprits or guilt by association? Genes Cancer 1:7(753-763)2010 Sep 2

20663872. Jayadeva G, Kurimchak A, Garriga J, Sotillo E, Davis AJ, Haines DS, Mumby M, Graña X, B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation. J Biol Chem 285:39(29863-73)2010 Sep 24

20025508. Ramkumar P, Smith BA, Akinbamidele AC, Kapcia J, Beauparlant SL, Haines DS, Generation and characterization of novel monoclonal antibodies recognizing UBXD1. Hybridoma (Larchmt) 28:6(459-62)2009 Dec

19061897. Bhattacharya S, Shcherbik N, Vasilescu J, Smith JC, Figeys D, Haines DS, Identification of lysines within membrane-anchored Mga2p120 that are targets of Rsp5p ubiquitination and mediate mobilization of tethered Mga2p90. J Mol Biol 385:3(718-25)2009 Jan 23

18212250. Li JG, Haines DS, Liu-Chen LY, Agonist-promoted Lys63-linked polyubiquitination of the human kappa-opioid receptor is involved in receptor down-regulation. Mol Pharmacol 73:4(1319-30)2008 Apr

17719829. Bhattacharya S, Zoladek T, Haines DS, WW domains 2 and 3 of Rsp5p play overlapping roles in binding to the LPKY motif of Spt23p and Mga2p. Int J Biochem Cell Biol 40:1(147-57)2008

17483323. Carbone CJ, Graña X, Reddy EP, Haines DS, p21 loss cooperates with INK4 inactivation facilitating immortalization and Bcl-2-mediated anchorage-independent growth of oncogene-transduced primary mouse fibroblasts. Cancer Res 67:9(4130-7)2007 May 1

17289586. Shcherbik N, Haines DS, Cdc48p(Npl4p/Ufd1p) binds and segregates membrane-anchored/tethered complexes via a polyubiquitin signal present on the anchors. Mol Cell 25:3(385-97)2007 Feb 9

16230384. Nagl NG Jr, Patsialou A, Haines DS, Dallas PB, Beck GR Jr, Moran E, The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 65:20(9236-44)2005 Oct 15

15466864. Shcherbik N, Kee Y, Lyon N, Huibregtse JM, Haines DS, A single PXY motif located within the carboxyl terminus of Spt23p and Mga2p mediates a physical and functional interaction with ubiquitin ligase Rsp5p. J Biol Chem 279:51(53892-8)2004 Dec 17

15352157. Shcherbik N, Haines DS, Ub on the move. J Cell Biochem 93:1(11-9)2004 Sep 1

12867034. Shcherbik N, Zoladek T, Nickels JT, Haines DS, Rsp5p is required for ER bound Mga2p120 polyubiquitination and release of the processed/tethered transactivator Mga2p90. Curr Biol 13:14(1227-33)2003 Jul 15

12861003. Garriga J, Bhattacharya S, Calbó J, Marshall RM, Truongcao M, Haines DS, Graña X, CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol Cell Biol 23:15(5165-73)2003 Aug

12717421. Bhattacharya S, Garriga J, Calbó J, Yong T, Haines DS, Graña X, SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 22:16(2443-51)2003 Apr 24

11870222. Shcherbik N, Kumar S, Haines DS, Substrate proteolysis is inhibited by dominant-negative Nedd4 and Rsp5 mutants harboring alterations in WW domain 1. J Cell Sci 115:Pt 5(1041-8)2002 Mar 1

10871862. Pan Y, Haines DS, Identification of a tumor-derived p53 mutant with novel transactivating selectivity. Oncogene 19:27(3095-100)2000 Jun 22

Return to top